FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118754991> ?p ?o ?g. }

• W3118754991 abstract "Background Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). In the last 5 years, increased awareness, availability of diagnostics based on flow cytometry, genetic testing, improved supportive care, use of reduced toxicity conditioning, and success of haploidentical donor HSCT have improved access to HSCT for children with PID in India. We present results on children with PID who underwent HSCT across India and the factors that influenced outcome. Patients and Methods We collected retrospective data on the outcome of HSCT for PID from seven centers. We analyzed the impact of the type of PID, conditioning regimen, time period of HSCT- before or after January 2016, graft versus host disease prophylaxis, cause of mortality and overall survival. Results A total of 228 children underwent HSCT for PID at a median age of 12 months (range, 1 to 220 months) with a median follow up of 14.4 months. Infants accounted for 51.3% of the cohort and the male female ratio was 3:1. SCID (25%) and HLH (25%) were the more frequent diagnoses. Matched family donor was available in 36.4% and 44.3% children had a haploidentical HSCT. Reduced and myeloablative conditioning regimens were used with 64% children receiving a treosulfan based conditioning regimen. Peripheral blood stem cells were the predominant graft source at 69.3%. The survival in infants (60.2%) was inferior to children aged over 1 year (75.7% p value = 0.01). Children with Wiskott Aldrich syndrome (74.3%) and chronic granulomatous disease (82.6%) had the best outcomes. The survival was superior in children receiving HSCT from a matched sibling (78%) versus an alternate donor HSCT (61% p value = 0.04). In the cohort transplanted after January 2016 survival improved from 26.8% to 77.5% (p value = 0.00). Infection remains the main cause of mortality at in over 50% children. The 5-year overall survival rate was 68%. Conclusion Survival of children with PID undergoing HSCT in India has improved dramatically in last 5 years. Alternate donor HSCT is now feasible and has made a therapeutic option accessible to all children with PID." @default.
• W3118754991 created "2021-01-18" @default.
• W3118754991 creator A5017204598 @default.
• W3118754991 creator A5024337993 @default.
• W3118754991 creator A5030029087 @default.
• W3118754991 creator A5032080212 @default.
• W3118754991 creator A5035464202 @default.
• W3118754991 creator A5048583711 @default.
• W3118754991 creator A5052543460 @default.
• W3118754991 creator A5053347244 @default.
• W3118754991 creator A5063242157 @default.
• W3118754991 creator A5065283870 @default.
• W3118754991 creator A5073620732 @default.
• W3118754991 creator A5079070873 @default.
• W3118754991 creator A5088844302 @default.
• W3118754991 creator A5089416884 @default.
• W3118754991 creator A5090931617 @default.
• W3118754991 date "2021-01-08" @default.
• W3118754991 modified "2023-10-18" @default.
• W3118754991 title "Multicenter Outcome of Hematopoietic Stem Cell Transplantation for Primary Immune Deficiency Disorders in India" @default.
• W3118754991 cites W1545823153 @default.
• W3118754991 cites W2006935117 @default.
• W3118754991 cites W2034091563 @default.
• W3118754991 cites W2036908772 @default.
• W3118754991 cites W2056037925 @default.
• W3118754991 cites W2067990511 @default.
• W3118754991 cites W2070414396 @default.
• W3118754991 cites W2075092149 @default.
• W3118754991 cites W2077324183 @default.
• W3118754991 cites W2083181001 @default.
• W3118754991 cites W2089324774 @default.
• W3118754991 cites W2101366992 @default.
• W3118754991 cites W2109208922 @default.
• W3118754991 cites W2122153475 @default.
• W3118754991 cites W2125520756 @default.
• W3118754991 cites W2277518476 @default.
• W3118754991 cites W2284962918 @default.
• W3118754991 cites W2417443195 @default.
• W3118754991 cites W2467216101 @default.
• W3118754991 cites W2498764951 @default.
• W3118754991 cites W2741182067 @default.
• W3118754991 cites W2754125581 @default.
• W3118754991 cites W2794587620 @default.
• W3118754991 cites W2884166609 @default.
• W3118754991 cites W2888262972 @default.
• W3118754991 cites W2899271238 @default.
• W3118754991 cites W2900988877 @default.
• W3118754991 cites W2912804186 @default.
• W3118754991 cites W2917228511 @default.
• W3118754991 cites W2918309724 @default.
• W3118754991 cites W2928462981 @default.
• W3118754991 cites W2928734528 @default.
• W3118754991 cites W2951750103 @default.
• W3118754991 cites W2957488451 @default.
• W3118754991 cites W2966818930 @default.
• W3118754991 cites W2978118489 @default.
• W3118754991 cites W2987332118 @default.
• W3118754991 cites W2988036531 @default.
• W3118754991 cites W2992369281 @default.
• W3118754991 cites W3011118539 @default.
• W3118754991 cites W3030797534 @default.
• W3118754991 cites W3043105233 @default.
• W3118754991 cites W3049091962 @default.
• W3118754991 doi "https://doi.org/10.3389/fimmu.2020.606930" @default.
• W3118754991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7819851" @default.
• W3118754991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33488609" @default.
• W3118754991 hasPublicationYear "2021" @default.
• W3118754991 type Work @default.
• W3118754991 sameAs 3118754991 @default.
• W3118754991 citedByCount "9" @default.
• W3118754991 countsByYear W31187549912022 @default.
• W3118754991 countsByYear W31187549912023 @default.
• W3118754991 crossrefType "journal-article" @default.
• W3118754991 hasAuthorship W3118754991A5017204598 @default.
• W3118754991 hasAuthorship W3118754991A5024337993 @default.
• W3118754991 hasAuthorship W3118754991A5030029087 @default.
• W3118754991 hasAuthorship W3118754991A5032080212 @default.
• W3118754991 hasAuthorship W3118754991A5035464202 @default.
• W3118754991 hasAuthorship W3118754991A5048583711 @default.
• W3118754991 hasAuthorship W3118754991A5052543460 @default.
• W3118754991 hasAuthorship W3118754991A5053347244 @default.
• W3118754991 hasAuthorship W3118754991A5063242157 @default.
• W3118754991 hasAuthorship W3118754991A5065283870 @default.
• W3118754991 hasAuthorship W3118754991A5073620732 @default.
• W3118754991 hasAuthorship W3118754991A5079070873 @default.
• W3118754991 hasAuthorship W3118754991A5088844302 @default.
• W3118754991 hasAuthorship W3118754991A5089416884 @default.
• W3118754991 hasAuthorship W3118754991A5090931617 @default.
• W3118754991 hasBestOaLocation W31187549911 @default.
• W3118754991 hasConcept C126322002 @default.
• W3118754991 hasConcept C141071460 @default.
• W3118754991 hasConcept C187212893 @default.
• W3118754991 hasConcept C2777408962 @default.
• W3118754991 hasConcept C2779019163 @default.
• W3118754991 hasConcept C2779134260 @default.
• W3118754991 hasConcept C2780611847 @default.
• W3118754991 hasConcept C2781413609 @default.
• W3118754991 hasConcept C2911091166 @default.
• W3118754991 hasConcept C71924100 @default.
• W3118754991 hasConceptScore W3118754991C126322002 @default.

• next